Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kallikrein pseudogene 1 (KLKP1) is a transcribed human pseudogene belonging to the kallikrein gene family, typically found within the kallikrein-kinin gene cluster on chromosome 19[2]. Unlike protein-coding kallikrein members, KLKP1 does not encode a functional enzyme but represents a genomic remnant related to active kallikrein serine proteases[1][2]. KLKP1 is often listed under aliases "KARMA," "KLK31P," "KRSP1," and "PsiKLK1."[2] While it is structurally similar to kallikrein genes and may be expressed at the RNA level, KLKP1 lacks critical coding features required for enzymatic activity, placing it in the category of pseudogenes[2]. No evidence supports KLKP1 as a therapeutic target or as a molecule with enzyme, receptor, or transporter activity in classical pharmacological terms. It does not interact directly with drugs, nor serve as a biomarker or present specific safety concerns. Its primary relevance is as a point of comparison or regulatory element in studies of kallikrein gene cluster genetics and expression[1][2]. KLKP1 is sometimes confused with functional kallikrein proteases (such as KLK1–KLK15), which play roles in cancer, inflammation, and cardiovascular biology, but KLKP1 itself is not a protein-coding gene and should not be treated as a therapeutic target[1][2]. The listing of this pseudogene may arise from its genomic context or association studies but current scientific understanding does not support its inclusion as a functional target. KLKP1 is best classified as a non-coding pseudogene and not a valid therapeutic or functional molecular target[2].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kallikrein pseudogene 1 (KLKP1).